Impact of Real-Time Continuous Glucose Monitoring Use on Glucose Variability and Endothelial Function in Adolescents with Type 1 Diabetes: New Technology—New Possibility to Decrease Cardiovascular Risk?
Table 2
Glucose variability during the study in the whole group and depending on HbA1c improvement.
Study group
HbA1c improvement
No HbA1c improvement
HbA1c (%)
Before the study After the study
9.35 ± 1.5 8.81 ± 1.8 <0.001
9.03 ± 1.35 8.04 ± 1.33 <0.001
10.03 ± 1.71 10.42 ± 1.60 0.102
Mean glucose (mg/dL)
1st week Last week
168.18 ± 33.9 144.8 ± 22.9 <0.001
164.44 ± 37 138.22 ± 31 <0.001
175.92 ± 22.77 158.46 ± 21.19 <0.001
Mean glucose SD (mg/dL)
1st week Last week
61.25 ± 14.5 53.55 ± 14.1 0.002
60.74 ± 15 51.67 ± 14 0.010
62.31 ± 12.43 57.46 ± 21.19 0.050
AUC > 140 mg/dL
1st week Last week
43.29 ± 26.1 25.23 ± 16.9 <0.001
41.23 ± 29 21.22 ± 15 <0.001
47.56 ± 18.47 33.58 ± 17.41 <0.001
AUC < 70 mg/dL
1st week Last week
0.58 ± 0.61 0.53 ± 0.53 0.591
0.73 ± 0.6 0.62 ± 0.5 0.439
0.29 ± 0.36 0.35 ± 0.36 0.576
Max glucose (mg/dL)
1st week Last week
365.15 ± 74.5 328.6 ± 67.2 0.002
344.37 ± 57 317.41 ± 55 0.004
380.6 ± 100.08 354.92 ± 82.98 <0.001
Min glucose (mg/dL)
1st week Last week
51.15 ± 12.5 47.5 ± 6.4 0.045
49.85 ± 13 46.07 ± 5 0.136
53.85 ± 10.05 50.46 ± 7.31 0.107
FMD (%)
Before the study After the study
10.9 ± 6.6 16.67 ± 8.5 <0.001
12.22 ± 5.41 19.27 ± 7.40 <0.001
8.18 ± 8.15 11.29 ± 8.35 0.089
Results of RT-CGM are presented as mean ± SD. : significant difference between two subgroups, considering the same time sensor usage (first or last week).
